Ovid Therapeutics Inc. (OVID) Reports Q2 EPS of $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
August 14, 2024 6:13 AM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
The analyst comments "The P2 trial for OV888 in CCM is expected to start in 2H24 and could rapidly establish POC. The lesions (complex blood vessel tangles) are clearly visible in patients and treatment with OV888 has the chance to resolve them (not certain but seen in animal models). Similarly, OV329 is a safer Vigabatrin by design, so confirming safety in humans is highly de-risking, we believe. We hosted OVID management at the recent BTIG... More
